Transcutaneous Bilirubin: How Does it Compare to the Lab?

SW Florida Point of Care Network February 24, 2011

Brad S. Karon, MD PhD

Associate Professor of Laboratory Medicine and Pathology

Department of Laboratory Medicine and Pathology

Mayo Clinic, Rochester MN





Relevant Financial Relationship(s) None

Off Label Usage

None




Outline

- Bilirubin
 Production
 Accumulation
- Bilirubin measurement
 Reference method
 Diazo methods
 Peroxidase (unbound bilirubin)
 Whole blood methods
 Bu and Bc
- Intra and Inter-lab method comparability
- Relationship between TcB and lab bilirubin



Bilirubin

- Principle breakdown product of heme
- Produced primarily in liver, spleen, bone marrow
- Highly insoluble





Bilirubin

• Accumulation

Adults: conjugated bilirubin >> unconjugated

Infants: Unconjugated bilirubin peaks between 3-6 days of life RBC fragility Immaturity of glucoronosyl transferase enzymes Other factors

 High unbound bilirubin levels toxic Kernicterus—frequency unknown, 100% preventable

Current guidelines

 AAP 2004: Assess every newborn for the risk of HB before D/C

2 options:

Pre-discharge TSB or TcB- plot on agebased nomogram

Assess clinical risk factors

 US Preventive Services Task Force 2009 No evidence screening reduces Kernicterus Possible harm thru overtreatment, increase cost



 Chromatographic separation identified 4 fractions:

Unconjugated bilirubin

Bilirubin monoglucuronide (singly conjugated)

Bilirubin diglucuronide (doubly conjugated)

Delta bilirubin (covalently bound to albumin)



Reference method

Doumas bilirubin method based on Jendrassik-Grof reaction

Reaction of bilirubin with diazotized sulfanilic acid (diazo reagent) to form azobilirubin dye

Accelerated by caffeine and sodium benzoate

USA reference lab Medical College Wisconsin

Reaction produces consistent results between labs Inter-lab CV ≤ 2% for values over 2 mg/dL Lo et al., Clin Biochem 2009



Diazo methods

Most common method used in labs

Without accelerant *mainly* conjugated and delta bilirubin react with diazo reagent—direct bilirubin

With accelerant all bilirubin reacts with diazo reagent—total bilirubin Total minus direct= indirect bilirubin Approximates unconjugated bilirubin

Peroxidase (unbound bilirubin) methods

Horseradish peroxidase catalyzes oxidation of unconjugated bilirubin

Protein-bound bilirubin is protected

Used as measure of unbound (free) bilirubin

Hemolysis, conjugated bilirubin, photoisomers, sample dilution, peroxidase concentration may all interfere/impact performance of assays

 Whole blood methods--photometric Bilirubin max absorbance ~ 450 nm

Neonatal blood devoid of other substances that absorb near 450 nm Makes direct measurement easier in neonates

Hemoglobin abs. similar at 450 and 540 nm Abs. 450 minus abs. 540 = bilirubin

Both two-point (requires centrifugation) and multi-point wavelength analyzers exist Multi-point whole blood bilirubin measurement on many blood gas/cooximetry analyzers

 Bu/Bc measurement (neonatal bilirubin) Vitros dry slide technology

Mordant separates absorbance spectra of conjugated and unconjugated bilirubin

Upper layers of slide filter out hemoglobin, protein (delta bilirubin), other interferences

Conjugated and unconjugated bilirubin measured separately

Total neonatal bilirubin = conj + unconj



Bu/Bc measurement

Direct photometric measurement of both unconjugated and total (minus delta) bilirubin

Less sensitive to effects of hemolysis Newer diazo methods also less sensitive Direct bili by diazo still problematic

Small sample volume



 Comparison of 9 methods within one academic medical center

Grohman et al., Pediatrics 2006;117:1174-83.

3 central lab methods

Hitachi 912, Dimension RxL, Vitros 250

3 whole blood methods

Twin Beam, OMNI S, ABL 735

3 transcutaneous methods

JM-102, JM-103, BiliCheck




 Comparison of 9 methods within one academic medical center

124 samples from 122 near-term/term infants

Plasma bilirubin conc. 0.5-22.7 mg/dL 9 infants (7%) above 15 mg/dL

3 lab methods correlated strongly Slopes 0.94-1.05 between all lab methods Intercepts < 0.2 mg/dL between all methods



 Comparison of 9 methods within one academic medical center

Compared to mean of 3 lab methods:

3 transcutaneous devices correlated well

Slopes 0.95-1.04

Intercepts -0.4 – 0.9 mg/dL

Correlation coefficients 0.961 to 0.966

3 whole blood devices correlated well

Slopes 0.97-1.03

Intercepts -1.0 to 0.1 mg/dL

Correlation coefficients 0.980 to 0.994



 Comparison of 9 methods within one academic medical center General conclusions (comparability)

Laboratory, whole blood and transcutaneous bilirubin methods agree well up to ~ 12-15 mg/dL

Can screen with either transcutaneous or whole blood bilirubin Confirm in lab above 12 (TcB) or 15 (whole blood) mg/dL

For lower values doesn't matter which method used



 Lo et al., Arch Pathol Lab Med 2008;132:1781-5

Reported distribution of values from ~ 5000 labs participating in bilirubin Proficiency Testing

10 lab methods including diazo, oxidase, photometric

One sample/survey prepared by adding NIST SRM 916 to pooled human sera Reference Doumas method used to grade all other methods

Lo et al.

Between 2003-2006 PT surveys contained one sample with reference value 19-22 mg/dL

In 2003 mean all method bias ~ 0.5 mg/dL

Mean bias (all methods) 1.5-2.0 mg/dL between 2003-2005, ~ 1.0 mg/dL in 2006

In 2006 most major methods overestimated total bilirubin by ~ 1.0 mg/dL

A few instruments differed widely from all others

- Lo et al.
- Instrument and method-dependent differences in calibrators responsible for positive bias
 Assigned calibrator values too high
- Proposed goal of 10% total error for bilirubin values > 10 mg/dL
- To reach goal quality of calibrators will need to be improved




Transcutaneous bilirubin

- Can TcB be used to screen for or assess risk of severe hyperbilirubinemia?
- What is relationship between TcB and lab bilirubin?
- Which lab bilirubin, does it matter?



At your institution who has oversight of TcB testing?

- 1. TcB testing not done
- 2. Nursing/pediatric service
- **3.** Lab
- 4. POCT program5. Don't know



- 4 studies BiliChek TcB underestimates serum bilirubin by 0.06-0.96 mg/dL
- 1 study BiliChek TcB overestimates serum bilirubin by ~ 1 mg/dL across a wide range of serum bilirubin values

 2 studies BiliChek TcB overestimates serum bilirubin at low concentrations, underestimates serum bilirubin at higher (> 12 mg/dL) levels


 No consistent association between method (photometric, diazo, BuBc) and mean bias

F MAYO CLIN

• Questions about TcB

What is sensitivity and specificity of high risk TcB for predicting high risk TsB?

If TcB is low risk, can we avoid blood draw (high sensitivity)?






• Mayo study

200 infants with clinical suspicion of hyperbilirubinemia, serum bilirubin ordered by physician in nursery


Measure BiliChek TcB within 30 minutes of serum bilirubin drawn

Measure serum bilirubin diazo method and direct photometric measurement of unconjugated bilirubin (BuBc)



Results: TcB vs. diazo TsB

Figure 1: Bland-Altmann Plot of TcB vs.TsB (diazo)




Median bias (TcB minus TsB) = 2.0 mg/dL



Bias relatively constant over range studied



Results: TcB vs. BuBc TsB



Median bias (TcB minus TsB) = 1.3 mg/dL

Bias relatively constant over range studied





What is the clinical impact of systematic overestimation of transcutaneous bilirubin?

Can TcB still be used to predict risk of hyperbilirubinemia?





- Each TcB and TsB value, combined with postnatal age in hours, used to determine risk zone (low, low-intermediate, highintermediate, high risk) according to Bhutani
- Sensitivity and specificity of high risk TcB for predicting high risk TsB was calculated



	Transcutaneous bilirubin			
Serum bilirubin (diazo)	Low or low- intermediate risk	Total		
Low or low- intermediate risk	48	77	125	
High-intermediate or high risk	1	51	52	
Total	49	128	177	

51/52 (98%) sensitivity for predicting high risk diazo TsB

48/125 (38%) specificity for predicting low risk diazo TsB

	Transcutaneous bilirubin			
Serum bilirubin (Vitros)	Low or low- intermediate risk	High-intermediate or high risk	Total	
Low or low- intermediate risk	35	29	64	
High-intermediate or high risk	4	63	67	
Total	39	92	131	

63/67 (94%) sensitivity for predicting high risk BuBc TsB 35/64 (55%) specificity for predicting low risk BuBc TsB

 Rodriguez-Capote et al. Clin Biochem 2009;42:176-9


- Compared 2 TcB methods to BuBc on Vitros
- Both TcB devices underestimated lab bilirubin
- Risk assessment effective only after adjustment for negative bias of TcB
- At Mayo BiliChek overestimated BuBc
- General consensus that TcB screening protocols need to be established institutionally Due to variability in lab bilirubin?



Which TcB meter does your facility use?

1. Respironics **BiliChek 2.** Drager (Minolta) **JM 103 3.** TcB not performed **4.** Don't know

MAYO CLINIC





• Unknown variables

Variability of TcB compared to lab bilirubin Mayo data: TcB SD at 13 mg/dL ~ 1 mg/dL Compares to lab method SD of ~ 0.2 mg/dL at 20 mg/dL

Inter-institution variability of TcB? No reference standard for TcB Can only compare to same lab method Use reference method or multiple methods tightly correlated to reference?


Does universal TcB screening increase treatment intensity?

 What is relationship between TcB and reference method for TSB?

Roche total bilirubin method recalibrated to better match reference method

Compare TcB to TSB before and after Roche recalibration

Compare Roche total serum bilirubin to reference method before and after recalibration using four samples with values assigned by reference method



	Cobas Unit 1	C	Cobas Unit 2		Reference method
		D: D::			performed by Childrens Hospital
	T. Bili	Dir Bili	T. Bili	Dir Bili	
Tube #1	10.7	0.2	11.0	0.2	10.2
	10.5	0.2	10.7	0.2	
Tube #2	13.8	0.2	14.3	0.2	13.08
	13.6	0.2	14	0.2	
Tube #3	18.0	0.2	18.9	0.2	17.06
	17.9	0.2	18.2	0.2	
Tube #4	21.1	0.2	22.1	0.2	19.98
	20.9	0.3	21.5	0.2	

Cobas Unit 1	Cobas Unit 2		2	Reference method performed by Childrens Hospital
T. Bili	Dir Bili	T. Bili	Dir Bili	
9.8	0.2	9.7	0.2	10.2
9.9	0.2	9.9	0.2	
12.9	0.3	12.9	0.2	13.08
12.8	0.3	12.8	0.3	
16.9	0.3	17.0	0.3	17.06
16.9	0.3	16.9	0.3	
19.9	0.3	19.8	0.3	19.98
19.8	0.3	19.8	0.3	
	9.8 9.9 12.9 12.8 16.9 16.9 16.9 19.9	9.8 0.2 9.9 0.2 12.9 0.3 12.8 0.3 16.9 0.3 16.9 0.3 19.9 0.3	9.80.29.79.90.29.912.90.312.912.80.312.816.90.317.016.90.316.919.90.319.8	9.80.29.70.29.90.29.90.29.90.29.90.212.90.312.90.212.80.312.80.316.90.317.00.316.90.316.90.319.90.319.80.3

- Mean (± SD) bias between TcB and TSB for 95 paired TcB/TSB samples before recalibration was 2.5 ± 1.3 mg/dL
- Mean (± SD) bias between TcB and TSB for 118 paired TcB/TSB samples performed after recalibration was 2.9 ± 1.4 mg/dL
- BiliChek TcB overestimates Doumas reference bilirubin by 2.9 mg/dL



• Future plans:

Study relationship between TcB and Roche TSB in multiple facilities, traceability to reference method in all sites

Determine whether universal TcB screening increases utilization of lab resources (TSB draws) or phototherapy



Conclusions

- Lab bilirubin measurement will vary by method and instrument
- Many lab methods overestimate bilirubin as measured by reference method
- Primary problem is calibration scheme used by vendors



Conclusions

- Relationship between TcB and lab bilirubin primarily function of lab variables
- BiliChek TcB appears to overestimate reference TSB will vary by instrument/institution
- Lack of standardization of lab methods makes inter-lab evaluation of TcB methods difficult
- Each institution must evaluate the effectiveness of TcB screening



Acknowledgements

- Walter J. Cook, MD
- Andrea C. Wickremasinghe, MD
- Amy K. Saenger, PhD
- Amy Wockenfus

